New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
06:24 EDTPGNXProgenics upgraded to Buy from Hold at Needham
Needham upgraded Progenics Pharmaceuticals with an $8 price target citing the company's positive Phase 2 data for prostate cancer.
News For PGNX From The Last 14 Days
Check below for free stories on PGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
08:47 EDTPGNXProgenics presents long term follow-up of Azedra Phase 2 trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use